Business update

LONDON, U.K. AND NEW YORK, U.S. (3 February 2026). Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, provides the following business update.

Operational and Commercial Progress

Since the Company's interim results for the six months ended 30 June 2025, Trellus Health has continued to make progress across its core strategic verticals, with particular momentum in the clinical trials sector.

Clinical Trials Vertical

• In October 2025, the Company entered into a 12-month contract with ICON plc, a global contract research organisation ("CRO"), to support recruitment and enrolment optimisation for an ongoing mid-stage immunology and inflammation clinical trial sponsored by Takeda. The contract includes an upfront fee, monthly management fees and milestone-based payments linked to defined performance indicators.

The Company has begun launching the program into agreed-upon sites.

• Later in October 2025, the Company entered into a second 12-month commercial contract with PSI Inc., another global CRO, to deploy its Trellus TrialSet™ solution across two late-stage immunology and inflammation clinical trials sponsored by Sanofi. This represents the Company's second commercial CRO contract following the launch of TrialSet™. The Company is implementing the programme now and expects to be fully launched in mid-Q1.
• In addition, Trellus Health® continues to support an ongoing Phase 2 IBD clinical trial pursuant to its licensing agreement with AstraZeneca.
• The Company has been granted preferred vendor status by both ICON plc and PSI Inc., which is expected to facilitate access to pharmaceutical sponsors and streamline future contracting processes.

Pharmaceutical and Patient Support Programmes

• The collaboration with Johnson & Johnson Health Care Systems Inc., signed in January 2025, continues to progress. During the pilot phase, engagement and satisfaction metrics were achieved, and in mid-January 2026 enrolment channels were broadened beyond the initial pilot funnel.
• In the second quarter of 2025, the Company renewed its agreement with Pfizer to license patient support educational content for inclusion in Pfizer's IBD digital application. Discussions are ongoing regarding a potential expansion with the expected renewal in 2026.

Platform and Product Development

• The Company continues to expand Trellus TrialSet™ as a condition-agnostic solution, extending its applicability beyond IBD into additional therapeutic areas.
• Ongoing enhancements to the Trellus Elevate® platform and user experience have supported engagement across active programmes.
• Work to achieve GDPR compliance is underway, alongside continued maintenance of the Company's SOC 2 Type II certification.

Funding and Outlook

The Company expects revenue for the year ended 2025 to be c. $545,000. As previously disclosed, the Company has further reduced its monthly cash burn to approximately $400,000, which was moderately offset by recurring monthly management fees generated during the second half of the year.

As announced previously, the Company has secured a £5 million convertible facility with Alumni Capital LLC, which was approved by shareholders on 20 January 2026. The Company believes that the net proceeds of the First Tranche Notes and Second Tranche Notes, which together total £737,500 in gross principal, will extend the Company's cash runway into late Q1 2026. The Directors remain in ongoing discussions regarding alternative sources of additional funding to further extend the Company's cash runway, irrespective of the utilisation of the Notes

The Board is focused on driving commercial momentum and expanding the Company's footprint through strategic partnerships, particularly within pharmaceutical and clinical trial verticals and has been very encouraged by the increasing validation of the Company's resilience-based methodology.

• Marla Dubinsky, CEO and Co-founder of Trellus Health plc said, "We are very pleased with the progress across our verticals during the second half of the year. Whilst reducing our monthly burn by c. 23% since the beginning of 2025, we successfully executed our patient support programme with J&J and developed and launched TrialSet™. We are now implementing TrialSet™ with our CRO partners and have commenced work with participating individual clinical sites."

"We continue to manage costs and working capital carefully and are encouraged by the growing validation of our differentiated, behavioural science-based approach. We remain focused on progressing commercial discussions and look forward to updating the market on further developments."